An Open-Label Trial of Riluzole in Patients With Treatment-Resistant Major Depression
OBJECTIVE: This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression. METHOD: After a 1-week drug-free period, subjects 18 years or older with a diagnosis of recurrent major depression and a Montgomery-Åsberg...
Saved in:
| Published in | The American journal of psychiatry Vol. 161; no. 1; pp. 171 - 174 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Washington, DC
American Psychiatric Publishing
01.01.2004
American Psychiatric Association |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | OBJECTIVE: This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression. METHOD: After a 1-week drug-free period, subjects 18 years or older with a diagnosis of recurrent major depression and a Montgomery-Åsberg Depression Rating Scale score ≥20 received riluzole monotherapy (100-200 mg day) openly for 6 weeks. RESULTS: Nineteen treatment-resistant depressed patients, 53% of whom were classified as having stage 2 treatment resistance or greater, received riluzole at a mean dose of 169 mg day. Significant improvement occurred during weeks 3 through 6 for all patients and weeks 2 through 6 for completers. CONCLUSIONS: Although preliminary, these results indicate that riluzole may have antidepressant properties in some patients. |
|---|---|
| AbstractList | Zarate et al determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression. After discussing the results they conclude that although preliminary, these results indicate that riluzole may have antidepressant properties in some patients. This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression.OBJECTIVEThis study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression.After a 1-week drug-free period, subjects 18 years or older with a diagnosis of recurrent major depression and a Montgomery-Asberg Depression Rating Scale score > or = 20 received riluzole monotherapy (100-200 mg/day) openly for 6 weeks.METHODAfter a 1-week drug-free period, subjects 18 years or older with a diagnosis of recurrent major depression and a Montgomery-Asberg Depression Rating Scale score > or = 20 received riluzole monotherapy (100-200 mg/day) openly for 6 weeks.Nineteen treatment-resistant depressed patients, 53% of whom were classified as having stage 2 treatment resistance or greater, received riluzole at a mean dose of 169 mg/day. Significant improvement occurred during weeks 3 through 6 for all patients and weeks 2 through 6 for completers.RESULTSNineteen treatment-resistant depressed patients, 53% of whom were classified as having stage 2 treatment resistance or greater, received riluzole at a mean dose of 169 mg/day. Significant improvement occurred during weeks 3 through 6 for all patients and weeks 2 through 6 for completers.Although preliminary, these results indicate that riluzole may have antidepressant properties in some patients.CONCLUSIONSAlthough preliminary, these results indicate that riluzole may have antidepressant properties in some patients. This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression. After a 1-week drug-free period, subjects 18 years or older with a diagnosis of recurrent major depression and a Montgomery-Asberg Depression Rating Scale score > or = 20 received riluzole monotherapy (100-200 mg/day) openly for 6 weeks. Nineteen treatment-resistant depressed patients, 53% of whom were classified as having stage 2 treatment resistance or greater, received riluzole at a mean dose of 169 mg/day. Significant improvement occurred during weeks 3 through 6 for all patients and weeks 2 through 6 for completers. Although preliminary, these results indicate that riluzole may have antidepressant properties in some patients. OBJECTIVE: This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression. METHOD: After a 1-week drug-free period, subjects 18 years or older with a diagnosis of recurrent major depression and a Montgomery-Åsberg Depression Rating Scale score ≥20 received riluzole monotherapy (100-200 mg day) openly for 6 weeks. RESULTS: Nineteen treatment-resistant depressed patients, 53% of whom were classified as having stage 2 treatment resistance or greater, received riluzole at a mean dose of 169 mg day. Significant improvement occurred during weeks 3 through 6 for all patients and weeks 2 through 6 for completers. CONCLUSIONS: Although preliminary, these results indicate that riluzole may have antidepressant properties in some patients. |
| Author | Luckenbaugh, David Charney, Dennis S. Manji, Husseini K. Quiroz, Jorge Payne, Jennifer L. Zarate, Carlos A. Sporn, Jonathan Denicoff, Kirk K. |
| Author_xml | – sequence: 1 givenname: Carlos A. surname: Zarate fullname: Zarate, Carlos A. – sequence: 2 givenname: Jennifer L. surname: Payne fullname: Payne, Jennifer L. – sequence: 3 givenname: Jorge surname: Quiroz fullname: Quiroz, Jorge – sequence: 4 givenname: Jonathan surname: Sporn fullname: Sporn, Jonathan – sequence: 5 givenname: Kirk K. surname: Denicoff fullname: Denicoff, Kirk K. – sequence: 6 givenname: David surname: Luckenbaugh fullname: Luckenbaugh, David – sequence: 7 givenname: Dennis S. surname: Charney fullname: Charney, Dennis S. – sequence: 8 givenname: Husseini K. surname: Manji fullname: Manji, Husseini K. |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15631940$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/14702270$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU1r3DAQhkVJaTab_oEeiii0N2_0YUv2MaRpG9iSEBLam5DtEdWilVxJPrS_PtruNoEcwjAMg5530Mx7go588IDQO0pWlEpxpqfJrvRmWlFBVyUkfYUWtOFNJRlrj9CCEMKqruE_j9FJSpvSEi7ZG3RMa0kYk2SB7s89vp7AV2vdg8N30WqHg8G31s1_gwNsPb7R2YLPCf-w-VdBQOdt6atbSDZl7TP-rjch4s8wRUjJBn-KXhvtErw91CW6_3J5d_GtWl9_vbo4X1eadyJXjdCib0fKaUtaIWvTCt71tB9l1xsYTEkwvew6KjltxpobMoyi8NA3IzMdX6JP-7lTDL9nSFltbRrAOe0hzEm1hMi2Llsv0Ydn4CbM0Ze_KcZI3fGGsAK9P0Bzv4VRTdFudfyj_l-rAB8PgE6DdiZqP9j0xDWC067ece2eG2JIKYJRg83liMHnqK1TlKidgWpnoCoGqmKgKiFpkbJn0sfpL4nO9qJ_b4-bvaB4AChLr3Y |
| CODEN | AJPSAO |
| CitedBy_id | crossref_primary_10_1016_j_ejphar_2008_11_018 crossref_primary_10_1080_10253890701223130 crossref_primary_10_1074_mcp_M111_016428 crossref_primary_10_1517_17460441_2013_804057 crossref_primary_10_1016_j_biopsych_2006_11_011 crossref_primary_10_3389_fphar_2022_884155 crossref_primary_10_1016_j_jpsychires_2016_01_003 crossref_primary_10_1016_j_neuropharm_2012_02_012 crossref_primary_10_1007_BF02629394 crossref_primary_10_1016_S1734_1140_13_71035_1 crossref_primary_10_1038_npp_2009_2 crossref_primary_10_1517_13543784_15_12_1545 crossref_primary_10_1016_j_cbpa_2009_04_617 crossref_primary_10_1016_j_psychres_2014_10_028 crossref_primary_10_1016_j_tips_2016_10_004 crossref_primary_10_1097_CHI_0b013e318185d2be crossref_primary_10_1136_bmjopen_2018_027770 crossref_primary_10_1038_mp_2011_162 crossref_primary_10_1016_j_pharmthera_2009_06_007 crossref_primary_10_1177_2470547018785625 crossref_primary_10_1111_j_1600_0447_2009_01529_x crossref_primary_10_1159_000529534 crossref_primary_10_1038_sj_mp_4002006 crossref_primary_10_3390_brainsci10080470 crossref_primary_10_3390_cells8020184 crossref_primary_10_1016_j_pnpbp_2010_06_013 crossref_primary_10_1097_FBP_0000000000000259 crossref_primary_10_1177_1073858409336093 crossref_primary_10_1038_npp_2011_198 crossref_primary_10_1016_j_neuropharm_2009_09_005 crossref_primary_10_1016_j_ddmec_2004_11_020 crossref_primary_10_1007_s40265_017_0702_8 crossref_primary_10_1517_14656566_7_17_2323 crossref_primary_10_1017_S1461145711001593 crossref_primary_10_31887_DCNS_2010_12_2_fmacmaster crossref_primary_10_1016_j_brainres_2010_10_108 crossref_primary_10_1002_ana_21181 crossref_primary_10_1007_s10562_022_04250_6 crossref_primary_10_1016_j_neuropharm_2011_08_040 crossref_primary_10_1007_s00213_013_3261_z crossref_primary_10_1016_j_biopsych_2011_03_038 crossref_primary_10_1093_ijnp_pyy094 crossref_primary_10_1016_j_biopsych_2004_11_023 crossref_primary_10_1007_s40265_016_0542_y crossref_primary_10_1016_j_neubiorev_2007_03_001 crossref_primary_10_31887_DCNS_2006_8_2_pholtzheimer crossref_primary_10_1017_S1461145712000545 crossref_primary_10_1016_j_euroneuro_2012_05_009 crossref_primary_10_1016_j_nurx_2005_12_007 crossref_primary_10_1007_s11164_023_05120_5 crossref_primary_10_1016_j_nurx_2005_12_009 crossref_primary_10_1124_pharmrev_120_000043 crossref_primary_10_1155_2017_4605971 crossref_primary_10_1016_j_nurx_2005_12_006 crossref_primary_10_1586_14737175_6_7_1017 crossref_primary_10_1016_j_nurx_2005_12_005 crossref_primary_10_1517_17425255_4_9_1223 crossref_primary_10_1038_tp_2016_212 crossref_primary_10_1016_j_bbr_2012_07_026 crossref_primary_10_1007_s10803_018_3562_5 crossref_primary_10_1016_j_jpsychires_2012_04_018 crossref_primary_10_1017_S1041610212000828 crossref_primary_10_1007_s00213_014_3676_1 crossref_primary_10_1007_s11920_008_0075_5 crossref_primary_10_1007_s00406_008_2012_3 crossref_primary_10_1111_jcpt_12497 crossref_primary_10_1111_j_1399_5618_2009_00752_x crossref_primary_10_1073_pnas_1609198113 crossref_primary_10_1093_ijnp_pyu039 crossref_primary_10_1007_s12640_010_9210_2 crossref_primary_10_1016_j_brainres_2011_01_100 crossref_primary_10_1002_aoc_3400 crossref_primary_10_1136_bmjopen_2011_000643 crossref_primary_10_1146_annurev_pharmtox_011613_135950 crossref_primary_10_1002_da_20800 crossref_primary_10_1111_j_1528_1167_2010_02907_x crossref_primary_10_1080_14728222_2020_1836160 crossref_primary_10_1371_journal_pone_0277718 crossref_primary_10_1016_j_neuropharm_2015_07_028 crossref_primary_10_1016_j_biopsych_2006_08_037 crossref_primary_10_1017_S1092852900010403 crossref_primary_10_1017_S1461145709009924 crossref_primary_10_1017_S1092852900016734 crossref_primary_10_3810_pgm_2010_07_2176 crossref_primary_10_2165_00023210_200822090_00004 crossref_primary_10_1371_journal_pcbi_1006938 crossref_primary_10_1016_j_neubiorev_2017_09_014 crossref_primary_10_1002_jhet_3753 crossref_primary_10_1016_j_ynstr_2016_08_002 crossref_primary_10_1517_13543784_2014_918951 crossref_primary_10_1016_j_psym_2013_02_002 crossref_primary_10_1016_j_wneu_2013_01_001 crossref_primary_10_1007_s00018_015_1937_8 crossref_primary_10_1016_j_biopsych_2007_09_012 crossref_primary_10_1111_j_1468_1331_2007_01843_x crossref_primary_10_1016_j_ejphar_2015_12_029 crossref_primary_10_1016_j_biomed_2012_05_002 crossref_primary_10_1016_j_pneurobio_2012_05_009 crossref_primary_10_1038_npp_2017_106 crossref_primary_10_1016_j_biopsych_2006_08_048 crossref_primary_10_1016_j_lfs_2021_119609 crossref_primary_10_1017_S1092852913000540 crossref_primary_10_1213_ANE_0000000000002594 crossref_primary_10_1016_j_pscychresns_2008_08_004 crossref_primary_10_1097_01_jcp_0000203228_64117_9f crossref_primary_10_1016_j_jad_2018_08_041 crossref_primary_10_1038_sj_npp_1301574 crossref_primary_10_3390_ijms25126357 crossref_primary_10_1176_foc_8_4_foc488 crossref_primary_10_1093_ijnp_pyu019 crossref_primary_10_1016_j_pbb_2011_09_010 crossref_primary_10_1007_s00115_007_2311_3 crossref_primary_10_1016_j_encep_2013_09_001 crossref_primary_10_1016_j_ibror_2019_01_001 crossref_primary_10_1016_j_biopsych_2013_01_021 crossref_primary_10_1016_j_jpsychires_2014_07_022 crossref_primary_10_1016_j_jad_2019_06_065 crossref_primary_10_4306_pi_2013_10_4_421 crossref_primary_10_1016_j_bbr_2015_06_022 crossref_primary_10_1007_s00702_011_0630_9 crossref_primary_10_1517_13543776_2014_999764 crossref_primary_10_1089_cap_2010_0154 crossref_primary_10_1016_j_jagp_2013_06_003 crossref_primary_10_1016_j_biopsych_2012_03_029 crossref_primary_10_1007_s00213_011_2403_4 crossref_primary_10_3389_fnbeh_2014_00189 crossref_primary_10_1038_npp_2011_338 crossref_primary_10_1016_j_ejphar_2014_07_046 crossref_primary_10_3389_fpsyt_2020_595584 crossref_primary_10_2165_11599770_000000000_00000 crossref_primary_10_1016_j_biopsych_2010_06_016 crossref_primary_10_1016_j_neuropharm_2009_12_004 crossref_primary_10_1002_glia_23143 crossref_primary_10_1007_s00702_013_1130_x crossref_primary_10_1016_j_pharmthera_2011_09_006 crossref_primary_10_1038_npp_2009_191 crossref_primary_10_1016_j_pbb_2018_03_008 crossref_primary_10_1016_j_neuropharm_2011_09_010 crossref_primary_10_1016_j_bbr_2010_07_002 crossref_primary_10_1089_jpm_2008_9828 crossref_primary_10_1016_j_lfs_2023_122025 crossref_primary_10_1007_s00213_003_1756_8 crossref_primary_10_1254_fpj_136_137 crossref_primary_10_1176_appi_focus_10_4_452 crossref_primary_10_1016_j_neubiorev_2014_08_017 crossref_primary_10_1038_npp_2009_180 crossref_primary_10_1176_appi_focus_12_2_152 crossref_primary_10_1016_j_pnpbp_2017_10_002 crossref_primary_10_1017_S1092852912000971 crossref_primary_10_1517_14728214_10_4_827 crossref_primary_10_1016_j_biopsych_2012_10_012 crossref_primary_10_1002_msj_20042 crossref_primary_10_1097_JCP_0000000000000693 crossref_primary_10_1002_msj_20043 crossref_primary_10_1111_j_1601_5215_2012_00675_x crossref_primary_10_1586_14737175_8_1_93 crossref_primary_10_1097_HRP_0000000000000030 crossref_primary_10_1176_appi_ajp_163_1_153 crossref_primary_10_3109_15622975_2011_580778 crossref_primary_10_1038_sj_npp_1301652 crossref_primary_10_1089_cap_2010_0009 crossref_primary_10_1016_j_bbr_2018_04_042 crossref_primary_10_1097_BRS_0b013e3182a7e9b0 crossref_primary_10_1080_07853890802409489 crossref_primary_10_1517_17460441_2_10_1369 crossref_primary_10_1017_S0033291714001603 crossref_primary_10_1016_j_yebeh_2012_01_007 crossref_primary_10_1146_annurev_pharmtox_010617_052823 crossref_primary_10_1155_2015_189307 crossref_primary_10_1096_fj_08_106450 crossref_primary_10_1176_appi_focus_19203 crossref_primary_10_1111_j_1399_5618_2011_00971_x crossref_primary_10_4103_jmedsci_jmedsci_36_19 crossref_primary_10_1176_jnp_2010_22_3_256 crossref_primary_10_1097_01_jcp_0000245567_29531_d6 crossref_primary_10_1017_S1461145709000169 crossref_primary_10_1080_15622970701420481 crossref_primary_10_1016_j_pbb_2011_03_021 crossref_primary_10_1038_sj_mp_4001521 crossref_primary_10_1176_appi_ajp_162_12_2379 crossref_primary_10_1590_S1516_44462006005000058 crossref_primary_10_1371_journal_pone_0088617 crossref_primary_10_1016_j_jpba_2017_08_045 crossref_primary_10_1155_2019_7943481 crossref_primary_10_1007_s11920_007_0063_1 crossref_primary_10_1371_journal_pone_0201092 crossref_primary_10_1097_01_yct_0000263257_44539_23 crossref_primary_10_1016_j_biopsych_2005_10_021 crossref_primary_10_1097_01_PSYPHR_0000410133_47951_30 crossref_primary_10_3109_10673229_2010_511059 crossref_primary_10_1517_14728210903107751 crossref_primary_10_1016_j_brainres_2012_03_066 crossref_primary_10_1038_s41380_022_01787_1 crossref_primary_10_1590_S1516_44462005000300016 crossref_primary_10_31887_DCNS_2017_19_1_rmcintyre crossref_primary_10_1038_nrd2462 crossref_primary_10_1016_j_biopsych_2005_04_043 crossref_primary_10_1038_mp_2015_91 crossref_primary_10_1038_mp_2015_92 crossref_primary_10_1016_j_curtheres_2019_100566 crossref_primary_10_2165_11530280_000000000_00000 crossref_primary_10_1111_j_1751_7893_2008_00072_x crossref_primary_10_1016_j_bcp_2009_04_008 crossref_primary_10_1016_j_ddmec_2005_11_005 crossref_primary_10_1016_j_pnpbp_2015_02_015 crossref_primary_10_1186_s11689_017_9186_9 crossref_primary_10_1038_sj_npp_1301178 crossref_primary_10_1016_j_brainres_2012_03_053 crossref_primary_10_1016_j_euroneuro_2006_01_003 crossref_primary_10_1016_j_biopsych_2012_05_003 crossref_primary_10_1177_1073858410361780 crossref_primary_10_1038_tp_2017_33 crossref_primary_10_3402_ejpt_v6_27660 crossref_primary_10_1007_s11596_014_1362_5 crossref_primary_10_1007_s00441_013_1664_0 |
| Cites_doi | 10.1038/sj.mp.4001087 10.1016/S0304-3940(01)02098-5 10.1056/NEJM199403033300901 10.1192/bjp.134.4.382 10.1016/S0014-2999(00)00709-3 10.1038/87865 10.4088/JCP.v64n0108 10.1016/S0006-3223(99)00230-9 10.1523/JNEUROSCI.22-08-03251.2002 10.4088/JCP.v60n0203 10.1016/0924-977X(92)90034-6 10.1192/bjp.175.1.12 |
| ContentType | Journal Article |
| Copyright | 2004 INIST-CNRS Copyright American Psychiatric Association Jan 2004 |
| Copyright_xml | – notice: 2004 INIST-CNRS – notice: Copyright American Psychiatric Association Jan 2004 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 |
| DOI | 10.1176/appi.ajp.161.1.171 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1535-7228 |
| EndPage | 174 |
| ExternalDocumentID | 572399861 14702270 15631940 10_1176_appi_ajp_161_1_171 10.1176/appi.ajp.161.1.171 |
| Genre | Clinical Trial Journal Article |
| GroupedDBID | --- --Z -DZ -~X .55 .GJ 08P 0WA 1HT 1QT 23M 2WC 354 4.4 53G 5GY 5RE 6J9 6TJ 7K8 85S 8F7 8R4 8R5 AAAHA AAIKC AAKAS AAMNW AAWTL AAWTO ABIVO ABPPZ ABZEH ACBMB ACGFO ACGOD ACHQT ACNCT ADBBV ADCOW ADZCM AENEX AETEA AFAZI AFFNX AFMIJ AFOSN AGHSJ AGNAY AHMBA AI. AIZTS ALMA_UNASSIGNED_HOLDINGS ASUFR BAJDF BAWUL BCR BENPR BKOMP BLC CS3 DIK E3Z EBS EJD EX3 F20 F5P F8P FA8 FJW G0H HF~ HZ~ J5H L7B MVM N4W N9A NEJ NHB OHT OK1 OVD P-O P2P PEA PQQKQ Q.- Q2X RAY RWL RXW RYA S10 SJN TAE TEORI TR2 TWZ UHB UKR ULE UPT UQL VH1 VVN WH7 WHG WOQ WOW X4V X6Y X7M XJT XOL XSW XZL YCJ YFH YOC YSK YWH YZZ ZCA ZGI ZRR ZXP ZY1 ~A~ ~G0 AAJMC AAYXX ADMHG CITATION H13 08R 1CY 1KJ 2QL 3O- 41~ AAJWC AAPBV AAQQT AAUGY AAYJJ ABPTK AERZD AFFDN AHJKT AKALU G8K GOZPB GRPMH IQODW LXL LXN SKT UBC YQI YQJ YRY YXB YYQ ZA5 ZHY ZKB ~X8 ABDPE CGR CUY CVF ECM EIF LPU NPM VXZ YIF YIN Z5M K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-a396t-56a6b8d131808674f8639b1bd79bfecffecefb79917315d43f0cd6d13eb5d2f93 |
| ISSN | 0002-953X |
| IngestDate | Fri Jul 11 05:31:32 EDT 2025 Sun Jun 29 15:27:32 EDT 2025 Wed Feb 19 01:40:37 EST 2025 Sun Oct 22 16:06:57 EDT 2023 Tue Jul 01 01:51:26 EDT 2025 Thu Apr 24 23:12:46 EDT 2025 Wed Jul 24 08:10:59 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Mood disorder Human Treatment resistance Psychotropic Toxicity Benzothiazole Treatment efficiency Depression Recurrent Riluzole Dose activity relation Symptomatology Chemotherapy Treatment Follow up study Antidepressant agent Evolution Severity score Comparative study |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-a396t-56a6b8d131808674f8639b1bd79bfecffecefb79917315d43f0cd6d13eb5d2f93 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 |
| PMID | 14702270 |
| PQID | 220493502 |
| PQPubID | 40661 |
| PageCount | 4 |
| ParticipantIDs | proquest_miscellaneous_80078400 proquest_journals_220493502 pubmed_primary_14702270 pascalfrancis_primary_15631940 crossref_citationtrail_10_1176_appi_ajp_161_1_171 crossref_primary_10_1176_appi_ajp_161_1_171 appi_journals_10_1176_appi_ajp_161_1_171 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20040101 2004-01-01 2004 2004-Jan |
| PublicationDateYYYYMMDD | 2004-01-01 |
| PublicationDate_xml | – month: 01 year: 2004 text: 20040101 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Washington, DC |
| PublicationPlace_xml | – name: Washington, DC – name: United States – name: Washington |
| PublicationTitle | The American journal of psychiatry |
| PublicationTitleAlternate | Am J Psychiatry |
| PublicationYear | 2004 |
| Publisher | American Psychiatric Publishing American Psychiatric Association |
| Publisher_xml | – name: American Psychiatric Publishing – name: American Psychiatric Association |
| References | R1611CHDJFFCI R1611CHDBHDAJ R1611CHDDGDIA R1611CHDFEDGB R1611CHDBIEJD R1611CHDFHGGI R1611CHDGJAJB R1611CHDBJBEJ R1611CHDFJDJJ R1611CHDHEAJJ R1611CHDEDEHA R1611CHDCEDAE R1611CHDIAEEC R1611CHDGFCJJ |
| References_xml | – ident: R1611CHDCEDAE doi: 10.1038/sj.mp.4001087 – ident: R1611CHDHEAJJ – ident: R1611CHDBIEJD – ident: R1611CHDDGDIA doi: 10.1016/S0304-3940(01)02098-5 – ident: R1611CHDIAEEC doi: 10.1056/NEJM199403033300901 – ident: R1611CHDGJAJB doi: 10.1192/bjp.134.4.382 – ident: R1611CHDBJBEJ doi: 10.1016/S0014-2999(00)00709-3 – ident: R1611CHDFHGGI doi: 10.1038/87865 – ident: R1611CHDFEDGB doi: 10.4088/JCP.v64n0108 – ident: R1611CHDGFCJJ doi: 10.1016/S0006-3223(99)00230-9 – ident: R1611CHDFJDJJ doi: 10.1523/JNEUROSCI.22-08-03251.2002 – ident: R1611CHDEDEHA doi: 10.4088/JCP.v60n0203 – ident: R1611CHDJFFCI doi: 10.1016/0924-977X(92)90034-6 – ident: R1611CHDBHDAJ doi: 10.1192/bjp.175.1.12 |
| SSID | ssj0000372 |
| Score | 2.2967749 |
| Snippet | OBJECTIVE: This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major... This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression. After a... Zarate et al determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression. After discussing the... This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major... |
| SourceID | proquest pubmed pascalfrancis crossref appi |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 171 |
| SubjectTerms | Adolescent Adult Aged Anticonvulsants - administration & dosage Anticonvulsants - therapeutic use Antidepressants Biological and medical sciences Depressive Disorder, Major - diagnosis Depressive Disorder, Major - drug therapy Drug Resistance Drug therapy Female Humans Male Medical sciences Mental depression Middle Aged Neuropharmacology Pharmacology. Drug treatments Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Recurrence Riluzole - administration & dosage Riluzole - therapeutic use Severity of Illness Index Surveys and Questionnaires |
| Title | An Open-Label Trial of Riluzole in Patients With Treatment-Resistant Major Depression |
| URI | http://dx.doi.org/10.1176/appi.ajp.161.1.171 https://www.ncbi.nlm.nih.gov/pubmed/14702270 https://www.proquest.com/docview/220493502 https://www.proquest.com/docview/80078400 |
| Volume | 161 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBASQtwJg-EHHpCqlCZx4uYxgqINtK6UVhq8RHHioE7Fjdr0ZX-JP8lx7MQJHeOiSFHlxk7q8_Xcci4IvQKZxwl1PZvmWWoT0HBtlnqBnWd-yGSFMlq9MT2dBMcL8uHcP-_1frSilnYlG6SXV-aV_A9VYQzoKrNk_4GyzaIwAJ-BvnAGCsP5r2gcga5XcGEDJbmMGV8qzXKzXO0uZdSgqZuqk9iasHIbrGypOYqy_z25WG9MRKxoq6tzk3ci2kUmujHSleM5mkXzsQ4hWa23xkc6jb5Mxu1Amn7jb_60OJmdfVVO_M23BmKfp2ezSdu133FNGKdk82TT-nGW6R7eDEcO_aonMMijmgnLFrs6abzm0qpmeweOiuc6qoeLFt-OavqzLxloVRK5kBmCF8UAlhvAUU9tl-H-RTw2QYtg6QK_IsMb6KYLNomUAu9OPhqx71G3trXkD6oztGjwZv-uoADIwY4ydKdItvC_zFVDld9bPJXmM7-H7mqTBUcKf_dRj4sH6NapDsp4iBaRwAaGuIIhXue4hiFeClzDEEsY4itgiCsYYgPDR2jxfjx_e2zrbh124oVBaftBErBR5oCQADOZknwEyi9zWEZDlvNURifxnFGwR6jn-Bnx8mGaBXA9Z37m5qH3GB2IteBPEZY9zihnzCU-JSQJRxlLwPJmDvdAn-fcQq_l7sUa99u4smRpEFejsNExbHQMB3Us5NQ7HKe66r1svrK6dk6_mVOomi_XXn3UIZyZovFiocOakuaJXRdMc88fuhZ62XwLnF2-rksEX--28Uiq7yBiLfREkd-sTKis_Dl89qdbH6LbKtJMugyfo4Nys-MvQIku2VEF3p--Osti |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+open-label+trial+of+riluzole+in+patients+with+treatment-resistant+major+depression&rft.jtitle=The+American+journal+of+psychiatry&rft.au=ZARATE%2C+Carlos+A&rft.au=PAYNE%2C+Jennifer+L&rft.au=QUIROZ%2C+Jorge&rft.au=SPORN%2C+Jonathan&rft.date=2004&rft.pub=American+Psychiatric+Association&rft.issn=0002-953X&rft.eissn=1535-7228&rft.volume=161&rft.issue=1&rft.spage=171&rft.epage=174&rft_id=info:doi/10.1176%2Fappi.ajp.161.1.171&rft.externalDBID=n%2Fa&rft.externalDocID=15631940 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-953X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-953X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-953X&client=summon |